PVLA
Palvella Therapeutics, Inc.
Price Chart
Latest Quote
$113.10
+0.47 (+0.42%)
Current Price
| Previous Close | $112.63 |
| Open | $115.70 |
| Day High | $116.60 |
| Day Low | $110.96 |
| Volume | 383,247 |
Stock Information
| Shares Outstanding | 14.34M |
| Total Debt | $20.38M |
| Cash Equivalents | $261.85M |
| Net Income | $-49.30M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $1.62B |
| EPS (TTM) | $-4.17 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $1.38B |
| Income | $-49.30M |
| Book/sh | $16.23 |
| Cash/sh | $18.26 |
| Employees | 29 |
Financial Ratios
| Quick Ratio | 28.73 |
| Current Ratio | 28.88 |
| Debt/Eq | 8.77 |
Returns & Margins
| ROA | -16.60% |
| ROE | -34.25% |
Ownership
| Insider Ownership | 11.65% |
| Institutional Ownership | 96.36% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -16.59 |
| P/B | 6.97 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $229.60 |
Technical Indicators
| SMA20 | $111.68 |
| SMA50 | $119.18 |
| SMA200 | $97.69 |
| RSI | 45.64 |
| ATR | 7.5507 |
| Shares Float | 9.58M |
| Short Float | 16.72% |
| Short Ratio | 10.28 |
| Rel Volume | 1.48 |
Performance History
| Week | +6.32% |
| Month | +3.57% |
| Quarter | -0.71% |
| 6 Months | +16.83% |
| YTD | +12.78% |
| Year | +432.49% |
| 3 Years | +49.92% |
| 5 Years | -59.37% |
| 10 Years | -19.21% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $113.10 | 383,200 |
| 2026-06-17 | $112.63 | 181,900 |
| 2026-06-16 | $110.12 | 251,700 |
| 2026-06-15 | $116.51 | 265,100 |
| 2026-06-12 | $108.81 | 360,800 |
| 2026-06-11 | $106.38 | 210,900 |
| 2026-06-10 | $102.19 | 359,400 |
| 2026-06-09 | $104.37 | 362,300 |
| 2026-06-08 | $105.25 | 368,300 |
| 2026-06-05 | $108.67 | 374,200 |
| 2026-06-04 | $114.82 | 207,700 |
| 2026-06-03 | $115.42 | 571,300 |
| 2026-06-02 | $104.67 | 200,400 |
| 2026-06-01 | $112.59 | 242,300 |
| 2026-05-29 | $118.46 | 155,700 |
| 2026-05-28 | $115.86 | 114,600 |
| 2026-05-27 | $116.26 | 113,700 |
| 2026-05-26 | $117.59 | 126,700 |
| 2026-05-22 | $113.99 | 146,400 |
| 2026-05-21 | $115.92 | 168,100 |
| 2026-05-20 | $115.50 | 221,000 |
| 2026-05-19 | $109.20 | 208,400 |
About Palvella Therapeutics, Inc.
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of angiokeratomas and other mTOR-driven skin diseases; and QTORIN pitavastatin for the treatment of disseminated superficial actinic porokeratosis. The company is based in Wayne, Pennsylvania.
đ° Latest News
Palvella Therapeutics (PVLA) Stock Valuation Check After Strong Recent Momentum
Simply Wall St. âĸ 2026-06-16T00:16:47Z
Palvellaâs QTORIN Trial Data Reframes Venous Malformation Outlook And Valuation
Simply Wall St. âĸ 2026-05-19T00:21:39Z
Palvella Therapeutics Q1 Earnings Call Highlights
MarketBeat âĸ 2026-05-08T22:13:26Z
Ligand Pharmaceuticals Q1 Earnings Call Highlights
MarketBeat âĸ 2026-05-08T06:06:36Z
New Palvella Director Brings Rare Disease Insight To Low Valued Stock
Simply Wall St. âĸ 2026-04-26T00:14:32Z
Inventiva Builds Up Leadership Team Ahead of Potential Commercialization
Exec Edge âĸ 2026-04-22T22:03:19Z
Palvellaâs Phase III Success And Fast Track Status Test Current Valuation
Simply Wall St. âĸ 2026-04-02T03:17:28Z
Palvella Therapeutics Inc (PVLA) Q4 2025 Earnings Call Highlights: Strategic Advances and ...
GuruFocus.com âĸ 2026-03-31T19:02:15ZPalvella Therapeutics Q4 Earnings Call Highlights
MarketBeat âĸ 2026-03-31T14:10:37Z
Palvella Stock Up 340% as Insider Sells Shares. Here's What the Move Does (And Does Not) Signal
Motley Fool âĸ 2026-03-25T22:45:00Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $5,818,000 | $4,317,000 | $0 | - |
| Total Expenses | $38,602,000 | $14,095,000 | $11,869,000 | $18,040,000 |
| Other Income Expense | $115,000 | $336,000 | $24,295,000 | $-174,000 |
| Other Non Operating Income Expenses | $727,000 | $2,947,000 | $712,000 | $126,000 |
| Net Non Operating Interest Income Expense | $-3,228,000 | $-3,675,000 | $6,265,000 | $-10,364,000 |
| Interest Expense Non Operating | $5,818,000 | $4,317,000 | $0 | - |
| Operating Expense | $38,602,000 | $14,095,000 | $11,869,000 | $18,040,000 |
| General And Administrative Expense | $15,761,000 | $5,944,000 | $3,076,000 | $4,156,000 |
| Total Other Finance Cost | - | - | $-6,265,000 | $10,364,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-41,715,000 | $-17,434,000 | $18,691,000 | $-27,552,000 |
| Net Interest Income | $-3,228,000 | $-3,675,000 | $6,265,000 | $-10,364,000 |
| Interest Income | $2,590,000 | $642,000 | $6,265,000 | - |
| Normalized Income | $-41,103,000 | $-14,823,000 | $-4,892,000 | $-27,262,771 |
| Net Income From Continuing And Discontinued Operation | $-41,715,000 | $-17,434,000 | $18,691,000 | $-27,552,000 |
| Total Operating Income As Reported | $-38,602,000 | $-14,095,000 | $-11,869,000 | $-18,040,000 |
| Net Income Common Stockholders | $-41,715,000 | $-17,434,000 | $17,915,000 | $-27,552,000 |
| Net Income | $-41,715,000 | $-17,434,000 | $18,691,000 | $-27,552,000 |
| Net Income Including Noncontrolling Interests | $-41,715,000 | $-17,434,000 | $18,691,000 | $-27,552,000 |
| Net Income Continuous Operations | $-41,715,000 | $-17,434,000 | $18,691,000 | $-27,552,000 |
| Pretax Income | $-41,715,000 | $-17,434,000 | $18,691,000 | $-28,578,000 |
| Interest Income Non Operating | $2,590,000 | $642,000 | $6,265,000 | - |
| Operating Income | $-38,602,000 | $-14,095,000 | $-11,869,000 | $-18,040,000 |
| Special Income Charges | - | $0 | $23,098,000 | $0 |
| Per Share | ||||
| Diluted EPS | $-3.71 | $-7.83 | $1.60 | $-2.46 |
| Basic EPS | $-3.71 | $-7.83 | $1.60 | $-2.46 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $-10,771 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-35,285,000 | $-10,506,000 | $-4,892,000 | $-17,740,000 |
| Total Unusual Items | $-612,000 | $-2,611,000 | $23,583,000 | $-300,000 |
| Total Unusual Items Excluding Goodwill | $-612,000 | $-2,611,000 | $23,583,000 | $-300,000 |
| EBITDA (Bullshit earnings) | $-35,897,000 | $-13,117,000 | $18,691,000 | $-18,040,000 |
| EBIT | $-35,897,000 | $-13,117,000 | $18,691,000 | $-18,040,000 |
| Diluted Average Shares | $11,251,250 | $2,225,934 | $11,221,307 | $11,221,307 |
| Basic Average Shares | $11,251,250 | $2,225,934 | $11,221,307 | $11,221,307 |
| Diluted NI Availto Com Stockholders | $-41,715,000 | $-17,434,000 | $17,915,000 | $-27,552,000 |
| Tax Provision | $0 | $0 | $0 | $-1,026,000 |
| Gain On Sale Of Security | $-612,000 | $-2,611,000 | $485,000 | $-300,000 |
| Research And Development | $22,841,000 | $8,151,000 | $8,793,000 | $13,884,000 |
| Selling General And Administration | $15,761,000 | $5,944,000 | $3,076,000 | $4,156,000 |
| Other Gand A | $15,761,000 | $5,944,000 | $3,076,000 | $4,156,000 |
| Preferred Stock Dividends | - | - | $776,000 | - |
| Other Special Charges | - | - | $-23,098,000 | - |
Fetched: 2026-06-21
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $27,983,000 | $62,607,000 | $-3,880,000 | $-23,174,000 |
| Total Assets | $59,559,000 | $88,234,000 | $7,548,000 | $16,524,000 |
| Total Non Current Assets | $572,000 | $0 | $0 | $0 |
| Current Assets | $58,987,000 | $88,234,000 | $7,548,000 | $16,524,000 |
| Other Current Assets | $1,005,000 | $2,296,000 | $198,000 | $471,000 |
| Receivables | $0 | $2,336,000 | $0 | - |
| Taxes Receivable | $0 | $1,978,000 | $0 | - |
| Accounts Receivable | $0 | $358,000 | $0 | - |
| Cash Cash Equivalents And Short Term Investments | $57,982,000 | $83,602,000 | $7,350,000 | $16,053,000 |
| Cash And Cash Equivalents | $57,982,000 | $83,602,000 | $7,350,000 | $16,053,000 |
| Debt | ||||
| Total Debt | $633,000 | $0 | - | - |
| Long Term Debt And Capital Lease Obligation | $431,000 | $0 | - | - |
| Current Debt And Capital Lease Obligation | $202,000 | - | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $31,576,000 | $25,627,000 | $11,428,000 | $39,698,000 |
| Total Non Current Liabilities Net Minority Interest | $20,232,000 | $13,589,000 | $9,068,000 | $33,916,000 |
| Other Non Current Liabilities | $17,760,000 | $11,942,000 | $8,054,000 | $32,417,000 |
| Derivative Product Liabilities | $2,041,000 | $1,647,000 | $1,014,000 | $1,499,000 |
| Current Liabilities | $11,344,000 | $12,038,000 | $2,360,000 | $5,782,000 |
| Other Current Liabilities | $2,901,000 | $3,167,000 | $169,000 | $159,000 |
| Payables And Accrued Expenses | $6,326,000 | $5,798,000 | $2,016,000 | $4,861,000 |
| Payables | $4,595,000 | $4,586,000 | $936,000 | $3,181,000 |
| Accounts Payable | $4,595,000 | $4,586,000 | $936,000 | $3,181,000 |
| Equity | ||||
| Common Stock Equity | $27,983,000 | $62,607,000 | $-74,483,000 | $-93,777,000 |
| Total Equity Gross Minority Interest | $27,983,000 | $62,607,000 | $-3,880,000 | $-23,174,000 |
| Stockholders Equity | $27,983,000 | $62,607,000 | $-3,880,000 | $-23,174,000 |
| Gains Losses Not Affecting Retained Earnings | $83,000 | $3,000 | $0 | - |
| Other Equity Adjustments | $83,000 | $3,000 | - | - |
| Retained Earnings | $-135,450,000 | $-93,735,000 | $-76,301,000 | $-94,992,000 |
| Preferred Stock Equity | - | - | $70,603,000 | $70,603,000 |
| Preferred Securities Outside Stock Equity | - | - | $70,603,000 | $70,603,000 |
| Other | ||||
| Ordinary Shares Number | $12,380,933 | $11,012,105 | $11,012,105 | $11,221,307 |
| Share Issued | $12,380,933 | $11,012,105 | $11,012,105 | $11,221,307 |
| Tangible Book Value | $27,983,000 | $62,607,000 | $-74,483,000 | $-93,777,000 |
| Invested Capital | $27,983,000 | $62,607,000 | $-74,483,000 | $-93,777,000 |
| Working Capital | $47,643,000 | $76,196,000 | $5,188,000 | $10,742,000 |
| Capital Lease Obligations | $633,000 | $0 | - | - |
| Total Capitalization | $27,983,000 | $62,607,000 | $-3,880,000 | $-23,174,000 |
| Additional Paid In Capital | $163,338,000 | $156,328,000 | $1,818,000 | $1,215,000 |
| Capital Stock | $12,000 | $11,000 | $70,603,000 | $70,603,000 |
| Common Stock | $12,000 | $11,000 | $0 | $0 |
| Preferred Stock | $0 | $0 | $70,603,000 | $70,603,000 |
| Long Term Capital Lease Obligation | $431,000 | $0 | - | - |
| Current Capital Lease Obligation | $202,000 | $0 | - | - |
| Pensionand Other Post Retirement Benefit Plans Current | $1,915,000 | $3,073,000 | $175,000 | $762,000 |
| Current Accrued Expenses | $1,731,000 | $1,212,000 | $1,080,000 | $1,680,000 |
| Net PPE | $572,000 | $0 | - | - |
| Gross PPE | $572,000 | $0 | - | - |
| Other Properties | $572,000 | - | - | - |
| Buildings And Improvements | $572,000 | $0 | - | - |
| Properties | $0 | $0 | - | - |
Fetched: 2026-06-21
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-25,006,000 | $-10,840,000 | $-13,703,000 | $-14,840,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-25,006,000 | $-10,840,000 | $-13,703,000 | $-14,840,000 |
| Cash Flow From Continuing Operating Activities | $-25,006,000 | $-10,840,000 | $-13,703,000 | $-14,840,000 |
| Operating Gains Losses | $612,000 | $2,611,000 | $-485,000 | $300,000 |
| Financing Activities | ||||
| Financing Cash Flow | $-660,000 | $87,089,000 | $5,000,000 | $9,566,000 |
| Cash Flow From Continuing Financing Activities | $-660,000 | $87,089,000 | $5,000,000 | $9,566,000 |
| Net Other Financing Charges | $-1,423,000 | $8,655,000 | $5,000,000 | - |
| Issuance Of Capital Stock | - | - | $0 | $9,532,000 |
| Net Preferred Stock Issuance | - | - | $0 | $9,532,000 |
| Preferred Stock Issuance | - | - | $0 | $9,532,000 |
| Other | ||||
| Issuance Of Debt | $0 | $78,434,000 | $0 | - |
| End Cash Position | $57,982,000 | $83,602,000 | $7,350,000 | $16,053,000 |
| Beginning Cash Position | $83,602,000 | $7,350,000 | $16,053,000 | $21,327,000 |
| Effect Of Exchange Rate Changes | $46,000 | $3,000 | $0 | - |
| Changes In Cash | $-25,666,000 | $76,249,000 | $-8,703,000 | $-5,274,000 |
| Proceeds From Stock Option Exercised | $763,000 | $0 | $0 | $34,000 |
| Net Issuance Payments Of Debt | $0 | $78,434,000 | $0 | - |
| Net Long Term Debt Issuance | $0 | $78,434,000 | $0 | - |
| Long Term Debt Issuance | $0 | $78,434,000 | $0 | - |
| Change In Working Capital | $3,816,000 | $-193,000 | $-3,149,000 | $1,621,000 |
| Change In Payables And Accrued Expense | $-40,000 | $3,288,000 | $-3,422,000 | $926,000 |
| Change In Accrued Expense | $-1,300,000 | $1,050,000 | $-1,177,000 | $-1,054,000 |
| Change In Payable | $1,260,000 | $2,238,000 | $-2,245,000 | $1,980,000 |
| Change In Account Payable | $1,260,000 | $2,238,000 | $-2,245,000 | $1,980,000 |
| Change In Prepaid Assets | $1,364,000 | $-1,503,000 | $273,000 | $695,000 |
| Change In Receivables | $2,492,000 | $-1,978,000 | $0 | - |
| Changes In Account Receivables | $387,000 | $0 | - | - |
| Other Non Cash Items | $5,880,000 | $3,346,000 | $-29,363,000 | $10,364,000 |
| Stock Based Compensation | $6,401,000 | $830,000 | $603,000 | $427,000 |
| Gain Loss On Investment Securities | $612,000 | $2,611,000 | $-485,000 | $300,000 |
| Net Income From Continuing Operations | $-41,715,000 | $-17,434,000 | $18,691,000 | $-27,552,000 |
Fetched: 2026-06-21